Source-grounded facts extracted from Ginkgo Bioworks Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Ginkgo Bioworks Holdings, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers.
“Pursuant to the foregoing vote, the compensation of the Company’s named executive officers was approved on an advisory basis.”
Ginkgo Bioworks Holdings, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“Pursuant to the foregoing vote, the ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved.”
Ginkgo Bioworks Holdings, Inc. shareholders approved Election of six nominees to serve as directors at the 2026-06-11 meeting.
“Pursuant to the foregoing votes, the six nominees listed above were elected to serve on the Company’s Board of Directors.”
Ginkgo Bioworks Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $19 million, net income $(76) million. Guidance reaffirmed.
“• First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities. • First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period.”
Ginkgo Bioworks Holdings, Inc. completed a disposition involving Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (closed 2026-04-03).
“On April 3, 2026, Ginkgo Bioworks, Inc. (the "Seller"), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the "Company") completed the previously announced transaction (the "Transaction") with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the "Purchaser") pursuant to the Stock Purchase Agreement, dated as of February 26, 2026 (the "Purchase Agreement"), by and among the Seller, the Company, the Purchaser and Ginkgo Biosecurity, LLC ("Biosecurity").”
Ginkgo Bioworks Holdings, Inc. entered into Stock Purchase Agreement with Tower Biosecurity, Inc. (effective 2026-02-26).
“On February 26, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Tower Biosecurity, Inc. (the “Purchaser”) and Ginkgo Biosecurity, LLC (“Biosecurity”).”
Steven Coen was appointed as Chief Financial Officer at Ginkgo Bioworks Holdings, Inc..
“Steven Coen, CPA, the Company’s Chief Accounting Officer, will become Chief Financial Officer, principal financial officer and principal accounting officer, effective upon Mr. Dmytruk’s resignation”
Mark Dmytruk resigned as Chief Financial Officer at Ginkgo Bioworks Holdings, Inc..
“Mark Dmytruk, the Company’s Chief Financial Officer and principal financial officer, gave notice on May 19, 2025 of his intention to resign from these roles at the Company on May 30, 2025 to accept a position at another organization”
Dr. Arie Belldegrun resigned as Director at Ginkgo Bioworks Holdings, Inc..
“On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.”
Dr. Sri Kosuri was appointed as Class B Director at Ginkgo Bioworks Holdings, Inc..
“On November 6, 2024, the Class B directors of the board of directors (the “Board”) of the Company appointed Dr. Sri Kosuri to the Board as a Class B director.”
Ginkgo Bioworks Holdings, Inc. announced a restructuring with charges of $18.0 million to $22.0 million affecting Cell Engineering segment (35% of the workforce).
“The Company currently estimates the costs for the reduction in force to range from $18.0 million to $22.0 million primarily in the Cell Engineering segment and consist of one-time cash severance and related costs.”
Ginkgo Bioworks Holdings, Inc. announced a restructuring with charges of at least $12 million affecting workforce (at least 35% of the workforce).
“for completion of the restructuring plan is not yet fully known; however, the Company expects the initial headcount reductions in June 2024 will result in cash costs of at least $12 million in severance and related separation costs. The Company will provide further details at its earnings call for the second quarter of 2024 and its Quarterly Report on Form 10-Q for”
Ginkgo Bioworks Holdings, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
“May 7, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE. Pursuant to Section 802.01C, the Company has a period of six months from receipt of the notice to regain compliance with the minimum stock price lis”
Ginkgo Bioworks Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $38 million.
“First quarter 2024 Total revenue of $38 million, down from $81 million in the comparable prior year period”
Ginkgo Bioworks Holdings, Inc. engaged Deloitte & Touche LLP as its auditor.
“On March 13, 2024, the Audit Committee appointed Deloitte & Touche LLP (“Deloitte”) as its new independent registered public accounting firm.”
Ginkgo Bioworks Holdings, Inc. reported financial results for fourth quarter 2023 and year ended December 31, 2023.
“On February 29, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2023 and year ended December 31, 2023.”
Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
“Ginkgo continues to expect Total revenue of $250 – $260 million in 2023”
Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $55 million, net income $(286) million. Guidance lowered.
“of next-generation biological intelligence capabilities, including AI-based epidemic forecasting Third Quarter 2023 Financial Highlights • Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment • Third”
Ginkgo Bioworks Holdings, Inc.: Board approved amendment and restatement of Bylaws, effective immediately, revising director nomination procedures, stockholder proposal requirements, disclosure obligations, proxy card color mandate, and removing stockholder list inspection requirement no longer required under DGCL (effective 2023-10-27).
“On October 27, 2023, the board of directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) approved an amendment and restatement of the Company’s Bylaws (the “Amended and Restated Bylaws”), effective immediately.”
Ginkgo Bioworks Holdings, Inc. reported second quarter ended June 30, 2023 results: revenue $81 million. Guidance reaffirmed.
“Second quarter 2023 Total revenue of $81 million”
Ginkgo Bioworks Holdings, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-16 meeting.
“The results of the vote were as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 4,328,967,974 697,993 14,355,978 1,545,509 214,945,590”
Ginkgo Bioworks Holdings, Inc. shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2023-06-16 meeting.
“The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 4,330,188,852 11,463,528 3,915,074 214,945,590”
Ginkgo Bioworks Holdings, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
“The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 4,548,208,562 9,208,067 3,096,415 0”
Ginkgo Bioworks Holdings, Inc. shareholders approved Election of director nominees designated to be elected by holders of Class A and Class B common stock (voting together as a single class): Arie Belldegrun, Marijn Dekkers, Kathy Hopinkah Hannan, Christian Henry, Reshma Kewalramani, Shyam Sankar, Harry E. Sloan at the 2023-06-16 meeting.
“Director nominees designated to be elected by holders of Class A and Class B common stock (voting together as a single class): Nominee Votes For Votes Against Abstentions Broker Non-Votes Arie Belldegrun 4,280,098,969 62,471,850 2,996,635 214,945,590 Marijn Dekkers 4,318,732,200 23,958,890 2,876,364 214,945,590 Kathy Hopinkah Hannan 4,330,845,522 5,216,853 9,505,079 214,945,590 Christian Henry 4,271,325,469 71,302,232 2,939,753 214,945,590 Reshma Kewalramani 4,227,332,531 117,314,365 920,558 214,945,590 Shyam Sankar 4,235,750,075 106,868,125 2,949,254 214,945,590 Harry E. Sloan 4,314,608,717 25,322,641 5,636,096 214,945,590”
Ginkgo Bioworks Holdings, Inc. shareholders approved Election of director nominees designated to be elected by holders of Class B common stock: Jason Kelly and Reshma Shetty at the 2023-06-16 meeting.
“Director nominees designated to be elected by holders of Class B common stock: Nominee Votes For Votes Against Abstentions Broker Non-Votes Jason Kelly 3,281,091,140 91,600 16,460 N/A Reshma Shetty 3,280,651,750 173,430 374,020 N/A”
Ginkgo Bioworks Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $81 million. Guidance reaffirmed.
“First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity business unit”
Steven P. Coen was appointed as Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc..
“In connection with Ms. Fallon’s resignation and subject to the approval of the Company’s Board of Directors, on May 5, 2023, the Company appointed Steven P. Coen, age 57, as its Chief Accounting Officer, effective May 15, 2023.”
Marie E. Fallon resigned as Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc..
“Marie E. Fallon informed Ginkgo Bioworks Holdings, Inc. (the “Company”) on May 1, 2023 of her intent to resign from her role as Chief Accounting Officer of the Company, effective May 15, 2023.”
Ginkgo Bioworks Holdings, Inc. reported fourth quarter 2022 and year ended December 31, 2022 results: revenue $478 million. Guidance reaffirmed.
“Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results $478 million of total revenue in 2022”
Ginkgo Bioworks Holdings, Inc. reported the year ended December 31, 2022 results: revenue $460 – 480 million. Guidance reaffirmed.
“Key Performance Highlights • Ginkgo reiterated its expectations of 55-60 new Cell Programs added to the Foundry platform in 2022 • Ginkgo continues to expect Total revenue of $460 – 480 million in 2022 o Preliminary unaudited Foundry revenue is expected to be below the previously disclosed guidance of $150 – $170 million in 2022 due to a subset of targeted”
Ginkgo Bioworks Holdings, Inc. reported full year 2022 results: revenue $460 – $480 million. Guidance raised.
“Ginkgo further revised its expectation for Total revenue from $425 – $440 million to $460 – $480 million in 2022”
Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue Third quarter 2022 Total revenue of $66 million.
“Third quarter 2022 Total revenue of $66 million, down from $78 million in the comparable prior year period, a decrease of 14%”
Kathy Hopinkah Hannan was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“On August 2, 2022, the Board of Directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) voted to appoint Kathy Hopinkah Hannan to the Board, effective as of August 2, 2022.”
Mark Dmytruk was appointed as Chief Financial Officer at Ginkgo Bioworks Holdings, Inc..
“Mark Dmytruk was appointed as Chief Financial Officer.”
Reshma Shetty was appointed as President and Chief Operating Officer at Ginkgo Bioworks Holdings, Inc..
“Ms. Shetty was appointed as President and Chief Operating Officer;”
Jason Kelly was appointed as Chief Executive Officer at Ginkgo Bioworks Holdings, Inc..
“Mr. Kelly was appointed as the Company’s Chief Executive Officer;”
Harry E. Sloan was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Shyam Sankar was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Reshma Kewalramani was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Christian Henry was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Marijn Dekkers was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Arie Belldegrun was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Reshma Shetty was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Jason Kelly was appointed as Director at Ginkgo Bioworks Holdings, Inc..
“Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.”
Harry E. Sloan departed as Director at Ginkgo Bioworks Holdings, Inc..
“Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.”
Laurence E. Paul departed as Director at Ginkgo Bioworks Holdings, Inc..
“Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.”
Dennis A. Miller departed as Director at Ginkgo Bioworks Holdings, Inc..
“Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.”
Timothy Leiweke departed as Director at Ginkgo Bioworks Holdings, Inc..
“Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.”
Isaac Lee departed as Director at Ginkgo Bioworks Holdings, Inc..
“Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.”
Joshua Kazam departed as Director at Ginkgo Bioworks Holdings, Inc..
“Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.